The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in predicting the therapeutic effect of chemotherapy against nasopharyngeal carcinoma

Cancer

Volumn 117, Issue 11, 2011, Pages 2435-2441

  Wang, Xiao Shen ^a   Zhang, Ying Jian ^a   Liu, Xiao Lan ^b   Zhou, Zheng Rong ^a   Hu, Chao Su ^a   Eisbruch, Avraham ^c  

^a FUDAN UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chemosensitivity; Induction chemotherapy; Nasopharyngeal carcinoma; Technetium 99m methoxyisobutyl isonitrile

Indexed keywords

CISPLATIN; FLUOROURACIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTINUOUS INFUSION; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

CHEMOSENSITIVITY; INDUCTION CHEMOTHERAPY; NASOPHARYNGEAL CARCINOMA; TECHNETIUM-99M METHOXYISOBUTYL ISONITRILE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958745055     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25802     Document Type: Article

References (31)

1. Teo P, Yu P, Lee WY, et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinomas evaluated by computer tomography. Int J Radiat Oncol Biol Phys. 1996;36:291-304. (Pubitemid 26359452)
2. Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261-270.
3. Fandi A, Altun M, Azli N, et al. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994;21:382-397. (Pubitemid 24191598)
4. Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the naso-pharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997;37:985-996. (Pubitemid 27230021)
5. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of 2 phase III trials. J Clin Oncol. 2005;23:1118-1124. (Pubitemid 46202267)
6. Zidan J, Kuten A, Robinson E. Intensive short cause chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma. Cancer. 1996;77:1973-1977. (Pubitemid 26142037)
7. Kuo WR, Lee KW, Ching FY, Jan YS, Juan KH. The effect of adjuvant chemotherapy for nasopharyngeal carcinoma: a preliminary report. Gaoxiong Yi Xue Ke Xue Za Zhi. 1993;9:9-17.
8. El-Weshi A, Khafaga Y, Allam A, et al. Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma - a phase II study. Acta Oncol. 2001;40:574-581. (Pubitemid 32916116)
9. Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005;103:850-857.
10. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58: 137-171. (Pubitemid 19172967)
11. Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989;30:301-311. (Pubitemid 19077319)
12. West DJ, Najm YC, Mistry R, et al. The localization of myocardial ischemia with technetium-99m-methoxyisobutyl-isonitrile and single photon emission computed tomography. Br J Radiol. 1989;62:303-313. (Pubitemid 19088495)
13. Fujii H, Nakamura K, Kubo A, et al. 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracy-clines in patients with breast cancer. Anticancer Res. 1998;18:4601-4605. (Pubitemid 29042029)
14. Ceriani L, Giovanella L, Bandera M, et al. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun. 1997;18:1087-1097. (Pubitemid 27523991)
15. Yamamoto Y, Nishiyama Y, Satoh K, et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med. 1998;39:1626-1629. (Pubitemid 28459901)
16. Bom HS, Kim YC, Song HC, et al. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med. 1998;39:91-94.
17. Kim YS, Cho SW, Lee KJ, et al. Tc-99m-MIBI SPECT is useful for noninvasively predicting the response of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma. Clin Nucl Med. 1999;24:874-879.
18. Kao CH, Tsai SC, Wang JJ, et al. Technetium-99m-sesta- methoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factor. Br J Haematol. 2001;113:369-374.
19. Taki J, Sumiya H, Asada N, et al. Assessment of P-glyco-protein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med. 1998;39:1179-1184. (Pubitemid 28326147)
20. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mito-chondrial and plasma membrane potentials on accumulation of hexakis (2 methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646-1653. (Pubitemid 20347047)
21. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m- tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med. 1996;37:1551-1556. (Pubitemid 26321646)
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
23. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977-984. (Pubitemid 23087894)
24. Waxman AD. Thallium-201 and technetium-99m methoxyisobutyl isonitrile (MIBI) in nuclear oncology. In: Sandler MP, Coleman RE, Wackers FJT, et al., eds. Diagnostic Nuclear Medicine. 3rd ed. Baltimore, Md: Williams and Wilkins; 1996:1261-1274.
25. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645. (Pubitemid 46211506)
26. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695-1704. (Pubitemid 350005151)
27. Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004;22:3053-3060. (Pubitemid 41103717)
28. Fountzilas G, Tolis C, Kalogera-Fountzila A, et al. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. Strahlenther Onkol. 2005;181: 223-230. (Pubitemid 40585541)
29. McGrogan BT, Gilmartin B, Carney DN, et al. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96-132.
30. Zhu X, Sui M, Fan W. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res. 2005; 25(3B):1953-1962. (Pubitemid 40904590)
31. Naito M, Matsuba Y, Sato S, et al. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res. 2002;8:582-588. (Pubitemid 34193980)